Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemodynamic effects of propofol, diazepam, and etomidate during induction for low ejection fraction CABG
IRCT2015082921669N2Phase 3Completed
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of propofol, diazepam and etomidate in cardiac disease, coronary arteriosclerosis and heart failure with reduced ejection fraction (HFrEF) (3 arms), sponsored by Mazandaran University of Medical Sciences. Primary endpoint: Hemodynamic changes during anesthesia induction. Started Feb 2014; status: completed.
02
Drugs
propofoldiazepametomidate
03
Conditions
cardiac diseasecoronary arteriosclerosisheart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on IRCT2015082921669N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2015082921669N2.